Generic Pharmaceutical Association praises Pres. Obama’s budget proposal
ARLINGTON, Va. President Barack Obama’s budget proposal, which includes an approval pathway for biosimilars, won praise from the Generic Pharmaceutical Association last week.
“For patients across the country suffering from cancer, diabetes and other diseases, the support stated by president Obama today for a workable biogenerics approval pathway is lifesaving news,” GPhA president and CEO Kathleen Jaeger said in a statement. “With countless patients struggling to pay the high costs of brand biopharmaceuticals, an approval pathway for safe, effective and affordable biogeneric medicines that provides access sooner rather than later is desperately needed.”
The model that the Hatch-Waxman Act of 1984 established for generic drugs provides a five-year period of data exclusivity for branded pharmaceutical drugs, which GPhA favors for biosimilars as well. However, the Biotechnology Industry Organization favors a 14-year data exclusivity period, saying that the Hatch-Waxman model would not provide sufficient time for biotech companies to recoup research and development expenses, thus stifling innovation.
Advanced Vision Research launches new OTC supplement for AMD
WOBURN, Mass. Advanced Vision Research has launched an OTC vitamin supplement for macular degeneration and diabetic retinopathy, the eye disease treatment company announced Thursday.
MacuTrition Eye Vitamin and Mineral Supplement contains fish oil omega-3 fatty acids, vitamin D and green tea extract for age-related macular degeneration and diabetic eye disease. AMD has no cure and is the leading cause of blindless in Americans older than 65. In addition, 5 million of the23 million Americans with diabetes have diabetic retinopathy and macular edema, and 97% of insulin-dependent diabetics will develop retinopathy.
“By targeting oxidation, inflammation and angiogenesis, we take a multi-pronged approach to maintaining eye health, especially in those with diabetes and macular degeneration, including those at risk, i.e. family members,” Advanced Vision Research CEO Jeffrey Gilbard stated.
Honey Naturals presents kids’ cough syrup at ECRM Cough, Cold and Allergy
SALT LAKE CITY Honey Naturals will be promoting its children’s cough syrup at the ECRM Cough, Cold and Allergy event in Jacksonville, Fla. next week, the company announced Wednesday.
The company’s new product, ZarBee’s Children’s Cough Syrup, is an all-natural, honey-based cough suppressant that provides children relief from coughs while simultaneously boosting the immune system.
“As a pediatrician, I found it extremely frustrating that I was unable to offer any help to my young patients to find relief from their coughs,” stated Zak Zarbock, a practicing pediatrician and developer of the cough syrup.
According to a recent Penn State research trial cited by Honey Naturals, dark honey has been proven to be safer and more effective than Dextromethorphan, the active ingredient in many cough medicines. ZarBee’s Cough Syrup uses a unique blend of dark honey known to be higher in antioxidants than traditional clover honey. The syrup also contains a child’s recommended daily serving of vitamin C and zinc gluconate.
Honey Naturals is looking to expand upon the regional sales success of its ZarBee’s products in the Mountain West and is planning to secure national distribution with one or more retail chains with a nationwide presence.